【摘要】 目的观察不同剂量瑞舒伐他汀对急性心肌梗死(acute myocardial infarction,AMI)患者血浆血清淀粉样蛋白A(SAA)、超敏C反应蛋白(hs-CRP)、N末端B型脑钠肽前体(NT-pro-BNP)水平的影响。方法 56例急性心肌梗死患者经PCI后,接受常规治疗,随机分为两组:A组(n=28)给予瑞舒伐他汀(10mg/d),B组(n=28)强化剂量(20mg/d)治疗,两组疗程均为3个月,观察心血管事件发生情况。并设健康对照组(n=24)。结果与对照组相比,A、B两组血清hs-CRP、SAA、NT-pro-BNP水平显著升高(P<0.05);治疗后1、2周A、B两组血清hsCRP、SAA、NT-pro-BNP水平均明显下降,差异有统计学意义(P<0.05);且B组下降幅度更大,差异有统计学意义(P<0.05)。随访3个月B组总心血管事件发生率明显低于A组,差异有统计学意义(P<0.05)。结论 PCI术后给予强化瑞舒伐他汀治疗短期即可显著降低血清炎性因子,且疗效优于常规治疗剂量,有利于AMI患者的恢复。更多还原

【Abstract】 Objective To observe the influence of the different doses of rosuvastati on serum hs-CRP,SAA and NT-pro-BNP in the patients with acute myocardial Infarction.Methods Fifty-six cases of acute myocardial infarction patients after PCI,accepted conventional treatment,they were randomly divided into two groups:group A(n = 28) was given rosuvastati(10 mg/d),and group B(n = 28) strengthen the dose(20 mg/d) treated,two groups of treatment were for 3 months,the cardiovascular events occur was observed.And 24 healthy subjects were selected as the control group.Results Before intervention,the serum hs-CRP,SAA and NT-pro-BNP levels in group A and group B were higher than that in control group(P < 0.05).After treatment of one,two weeks,the serum hs-CRP,SAA and NT-pro-BNP levels in group A and group B were decreased,the difference was statistically significant(P < 0.05).and the decline was even greater in group B,the difference was statistically significant(P < 0.05).Follow-up of 3 months B group always the risk of cardiovascular events was significantly lower than the group A,the difference was statistically significant(P < 0.05).Conclusion PCI postoperative to strengthen rosuvastati therapy short-term can significantly reduce serum inflammatory factor,and the curative effect is better than the conventional therapeutic dose,which is beneficial to the recovery of patients with AMI.更多还原